Susan A Berry

Emailberry002umnedu

Research activity per year

If you made any changes in Pure these will be visible here soon.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

Fingerprint

The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

1 Similar Profiles

7 Active
20 Finished

An open-label, multinational, multicenter, intravenous infusion study of the efficacy, safety, pharmacokinetics and pharmacodynamics of avalglucosidase alfa in treatment-naive
Berry, S. A.
SANOFI-AVENTIS US
3/31/21 → 12/31/23
Project: Research project
A Phase 1b Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Doses of ARCT-810 in Clinically Stable Patients with Ornithine Transcarbamylase Deficiency
Berry, S. A.
ARCTURUS THERAPEUTICS, INC
6/1/20 → 6/30/25
Project: Research project
A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects with Propionic or Methylmalonic Acidemia Followed by a 6-Month, Randomized, Double-blind, Placebo-controlled, 2-period Crossover and an Open-label, Long-term Extension
Berry, S. A.
HEMOSHEAR THERAPEUTICS, LLC
6/1/20 → 7/31/25
Project: Research project
Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
Berry, S. A.
CHILDREN'S RESEARCH INSTITUTE
9/17/19 → 7/31/22
Project: Research project
Data Monitoring Committee: "A Phase 3 randomized, multicenter, multinational, double-blinded studycomparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) andalglucosidase alfa in treatment-naive patients with late
Berry, S. A.
SANOFI-AVENTIS US
2/15/19 → 12/31/24
Project: Research project

137 Article
7 Review article
5 Comment/debate
4 Letter

Methionine synthase deficiency: Variable clinical presentation and benefit of early diagnosis and treatment
Kripps, K. A., Sremba, L., Larson, A. A., Van Hove, J. L. K., Nguyen, H., Wright, E. L., Mirsky, D. M., Watkins, D., Rosenblatt, D. S., Ketteridge, D., Berry, S. A., McCandless, S. E. & Baker, P. R., Mar 2022, In: Journal of Inherited Metabolic Disease. 45, 2, p. 157-168 12 p.
Research output: Contribution to journal › Article › peer-review
Rare presentation of FDX2-related disorder and untargeted global metabolomics findings
Aggarwal, A., Pillai, N. R., Billington, C. J., Schema, L. & Berry, S. A., Apr 2022, In: American Journal of Medical Genetics, Part A. 188, 4, p. 1239-1244 6 p.
Research output: Contribution to journal › Article › peer-review
ASL expression in ALDH1A1⁺ neurons in the substantia nigra metabolically contributes to neurodegenerative phenotype
Members of the UCDC, Oct 2021, In: Human Genetics. 140, 10, p. 1471-1485 15 p.
Research output: Contribution to journal › Article › peer-review

Open Access
Cobalamin J disease detected on newborn screening: Novel variant and normal neurodevelopmental course
Pillai, N. R., Miller, D., Pierpont, E. I., Berry, S. A. & Aggarwal, A., Jun 2021, In: American Journal of Medical Genetics, Part A. 185, 6, p. 1870-1874 5 p.
Research output: Contribution to journal › Article › peer-review
Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders
Longo, N., Diaz, G. A., Lichter-Konecki, U., Schulze, A., Inbar-Feigenberg, M., Conway, R. L., Bannick, A. A., McCandless, S. E., Zori, R., Hainline, B., Ah Mew, N., Canavan, C., Vescio, T., Kok, T., Porter, M. H. & Berry, S. A., Jan 2021, In: Molecular Genetics and Metabolism. 132, 1, p. 19-26 8 p.
Research output: Contribution to journal › Article › peer-review

Open Access
3 Scopus citations

Susan A Berry, Professor

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Network

Dive into details

An open-label, multinational, multicenter, intravenous infusion study of the efficacy, safety, pharmacokinetics and pharmacodynamics of avalglucosidase alfa in treatment-naive

A Phase 1b Randomized, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Doses of ARCT-810 in Clinically Stable Patients with Ornithine Transcarbamylase Deficiency

A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects with Propionic or Methylmalonic Acidemia Followed by a 6-Month, Randomized, Double-blind, Placebo-controlled, 2-period Crossover and an Open-label, Long-term Extension

Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)

Data Monitoring Committee: "A Phase 3 randomized, multicenter, multinational, double-blinded studycomparing the efficacy and safety of repeated biweekly infusions of neoGAA (GZ402666) andalglucosidase alfa in treatment-naive patients with late

Methionine synthase deficiency: Variable clinical presentation and benefit of early diagnosis and treatment

Rare presentation of FDX2-related disorder and untargeted global metabolomics findings

ASL expression in ALDH1A1⁺ neurons in the substantia nigra metabolically contributes to neurodegenerative phenotype

Cobalamin J disease detected on newborn screening: Novel variant and normal neurodevelopmental course

Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders

Susan A Berry, Professor

Personal profile

Expertise related to UN Sustainable Development Goals

Fingerprint

Network

Projects

Research output